In the wound healing process, neutrophils are the first inflammatory cells to move to the wound tissues. They sterilize wounds by killing microbes, and they stimulate other immune cells to protect the host from infection. In contrast, neutrophil-derived proteases cause damage to host tissues, so neutrophils play dual opposite roles in wound healing. Interleukin-17A (IL-17A) is a proinflammatory cytokine that promotes the recruitment of these cells. The role of this cytokine in the wound healing process is not fully clarified. In the present study, therefore, we examined how defect in IL-17A production affected the wound healing in skin. IL-17A-knockout (KO) mice showed promoted wound closure, myofibroblast differentiation and collagen deposition and decreased the neutrophil accumulation compared with wild-type (WT) mice. In contrast, the administration of recombinant IL-17A led to delayed wound closure, low collagen deposition and accelerated neutrophilic accumulation. In addition, the treatment of IL-17A-administered mice with a neutrophil elastase inhibitor improved the wound repair to the same level as that of WT mice. These results indicated that IL-17A hampered the wound healing process and suggested that neutrophilic inflammation caused by IL-17A may be associated with impaired wound healing in skin.
O R I G I N A L A R T I C L E

IL-17Apromotesneutrophilicinflammationanddisturbsacute
| INTRODUCTION
Wound healing processes are generally composed of inflammatory, proliferation and remodelling phases.
1,2 A variety of cytokines and growth factors, such as interleukin-1 (IL-1)-β, tumor necrosis factor (TNF)-α, transforming growth factor (TGF)-β, epidermal growth factor (EGF), platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF), [3] [4] [5] play critical roles in carrying these processes forward in a harmonized manner. 6 In contrast, chronic wounds often become intractable because of the prolonged accumulation of inflammatory cells such as neutrophils and the excessive production of proinflammatory cytokines and proteases.
7,8
Neutrophils quickly infiltrate wound tissues and then clean the wounds up through microbial sterilization and the removal of foreign compounds. 9 After their work is completed, these cells disappear from the wound tissues, and then, the inflammatory phase is terminated.
10
However, if neutrophils persist in wound tissues, excessive inflammatory cytokines and proteases are produced by these cells, and the wounds become refractory, 11 where the proteases secreted by activated neutrophils disrupt the growth factors necessary for the healing process. Interleukin-17A (IL-17A) induces neutrophilic inflammation and plays a critical role in the host defense against infectious pathogens.
12
This cytokine is also implicated in many autoimmune diseases, such as rheumatoid arthritis, psoriasis, multiple sclerosis and inflammatory bowel disease. 13 IL-17-producing helper T (Th) cells are a distinct subset from Th1 and Th2 cells and were therefore named Th17 cells.
14,15
In skin wounds, the major IL-17A-producing cells have been reported to be γδ T cells in the dermis, 16 dendritic epidermal T cells 17 and macrophages 18 rather than Th17 cells. In psoriasis, dermal γδ T cells were reported to produce a large amount of IL-17A upon stimulation with IL-23, which causes epidermal hyperplasia through the infiltration of inflammatory cells. 19 In previous studies investigating the role of IL-17A in skin wound healing, conflicting results have been reported, 17, 18 and the precise role of IL-17A in the wound healing process remains to be fully understood.
With this background, the current study was performed to clarify the role of IL-17A in the wound healing process using a mouse wound model. We investigated the wound healing process after full-thickness wounding in mice with genetic disruption of IL-17A. We found that IL-17A impaired the healing process by causing the persistent infiltration of neutrophils in wound tissues in the skin.
| MATERIALSANDMETHODS
| Animals
IL-17A-knockout (KO) mice were generated and established as described previously 20 and backcrossed to C57BL/6 mice for more than eight generations. C57BL/6 mice, purchased from CLEA Japan (Tokyo, Japan), were used as a wild-type (WT) control. Male or female 6-to 8-week-old mice were used in the experiments. All mice were kept under specific pathogen-free conditions in the Institute for Animal Experimentation, Tohoku University Graduate School of Medicine (Sendai, Japan). All experimental protocols described in this study were approved by the Ethics Review Committee for Animal Experimentation of Tohoku University.
| Woundcreationandtissuecollection
Mice were anaesthetized by intraperitoneal injection of 40 mg/kg sodium pentobarbital (NEMBTAL, Dainippon Sumitomo Pharma, Osaka, Japan). The dorsal hair was shaved to fully expose the skin.
Full-thickness wounds were created on the backs of mice using a 3-mm-diameter biopsy punch under sterile condition, and covered with a polyurethane film (Tegaderm Transparent Dressing, 3M Health Care, St. Paul, MN, USA) for an occlusive dressing. At specific time points, mice were sacrificed and wound tissues were harvested with an 8-mm-diameter biopsy punch.
| TreatmentwithrecombinantmurineIL-17A
Recombinant IL-17A (rIL-17A) was purchased from PEPROTECH (Rocky Hill, NJ, USA) and diluted with phosphate-buffered saline (PBS) containing 0.1% murine serum. PBS containing 0.1% murine serum was used as a vehicle control. After wounding, 20 ng of rIL-17A was applied to the wounds in WT mice.
| Measurementofwoundarea
Morphometric analysis was performed on digital images. At wounding and specific time points, the wounds were photographed. The wound area was measured by tracing the wound margin and calculating the pixel area using Axio Vision imaging software (Carl Zeiss Micro Imaging Japan, Tokyo, Japan). Percentage of wound closure was calculated using the following formula: % wound closure=(1−wound area at the indicated time point/wound area on day 0)×100. All analyses were performed under blinded conditions.
| Histologyandimmunohistochemistry
The wound tissues were fixed with a 4% paraformaldehyde- 
| ExtractionofRNAandquantitativereal-time
RT-PCR
Total RNA was extracted from wound tissues using ISOGEN (Nippon Gene Co. Ltd., Tokyo, Japan), and first-strand cDNA was synthesized using a PrimeScript first-strand cDNA synthesis kit (TaKaRa Bio Inc., Otsu, Japan), according to the manufacturer's instructions. The reaction efficiency with each primer set was determined using standard amplifications. Target gene expression levels and that of HPRT as a reference gene were calculated for each sample using the | 139 reaction efficiency. The results were analysed using a relative quantification procedure and are presented as expression relative to HPRT expression.
| Hydroxyprolineassay
Mice were sacrificed on day 3 after wounding, and the total hydroxyproline content of the wound tissues was assayed using the Woessner method. 21 
| MeasurementofTGF-β1concentrations
The wound tissues were homogenized with PBS, and the concentration of transforming growth factor (TGF)-β1 in the supernatants was measured using an enzyme-linked immunosorbent assay (ELISA) kit (eBioscience, San Diego, CA, USA). The detection limit was 8 pg/mL.
| Preparationofleucocytesinthewoundtissues
Tissue samples from the wounds were collected and teased apart using a stainless steel mesh in RPMI 1640 medium (Nipro, Osaka, 
| Analysisofleucocytefractionusing flowcytometry
The cells obtained from the wound tissues were stained with (Fig. S1 ). The stained cells were analysed using a BD FACS Canto II flow cytometer (BD Bioscience). The number of macrophages, neutrophils and lymphocytes was estimated by multiplying the total leucocyte number by the proportion of each fraction.
| IntracellularexpressionofIL-17A
Myeloid cells were stained with various mAbs, as described above.
Lymphoid 
| Administrationofneutrophilelastaseinhibitor
Sivelestat sodium hydrate (Elaspol®), a neutrophil elastase inhibitor, was purchased from Ono Pharmaceutical Co. (Osaka, Japan) and dissolved in normal saline at 100 μg/mL. To inhibit neutrophil elastase, WT mice treated with rIL-17A were injected intraperitoneally with sivelestat sodium hydrate (1 mg/kg) one day before and on days 0, 1 and 2 after wounding. As a control group for sivelestat sodium hydrate-treated mice, WT mice treated with rIL-17A were injected with normal saline at the same time points. As a control for rIL-17A-treated mice, PBS containing 0.1% murine serum was applied to the wounds in WT mice.
| Statisticalanalysis
Data were analysed using a statistical software package (SPSS 13.0J
for Windows, SPSS Japan, Tokyo, Japan) and expressed as the mean±standard deviation (SD). Data analysis was performed using the Welch's t-test. A P value <.05 was considered significant.
| RESULTS
| IL-17Adeficiencyleadstopromotedwound healing
To elucidate the effect of IL-17A deficiency on the process of wound healing, the wound closure was compared between WT and IL-17A-KO mice. As shown in Fig. 1a , b, wound closure was significantly promoted in IL-17A-KO mice compared with WT mice on days 3 and 5 after wounding. Next, we conducted a histological analysis of the wound tissues. In IL-17A-KO mice, the width of wounds was found to be markedly decreased and the granulation tissues were significantly well developed compared with WT mice on day 5 (Fig. 1c, d ). In addition, IL-17A-KO mice showed a marked increase in the number of myofibroblasts, an alternate indicator of wound healing, on day 5 after wounding ( Fig. 1e) . These results suggested that IL-17A may negatively regulate normal wound healing.
| EffectofIL-17Adeficiencyonwoundhealing-associated molecules
We next investigated the effect of IL-17A deficiency on collagen deposition. As shown in Fig. 2a , IL-17A-KO mice showed a significantly increased expression of COL1A1, a significant decrease in COL3A1 expression and a marked decrease in the ratio of COL3A1 to COL1A1 compared with WT mice on day 3 after wounding. In addition, the content of hydroxyproline, a collagen-specific amino acid, was found to be significantly increased in IL-17A-KO mice compared with that in WT mice on day 3 (Fig. 2b) . The production of TGF-β1, an important cytokine for collagen synthesis and granulation in wounds, was markedly promoted in IL-17A-KO mice compared to WT mice on day 2 (Fig. 2c ).
| IL-17Adeficiencyleadstoattenuated accumulationofneutrophils
IL-17A plays an important role in neutrophil recruitment. 22 Therefore,
we next analysed the accumulation of leucocyte in wound tissues. In wound tissues from IL-17A-KO mice, the number of neutrophils was found to be significantly decreased at 24 hours and that of macrophages was found to be significantly increased 3 hours after wounding compared with those from WT mice; in terms of the number of lymphocytes, there was no significant difference between the two groups (Fig. 2d) . Additionally, we examined the expression of chemokines in wound tissues, and the expression of KC mRNA was significantly lower in IL-17A-KO mice than that in WT mice 6 hours after wounding. In regard to that of MCP-1, MIP-1α and MIP-1β, there was no significant difference between the two groups (Fig. 2e) .
These results suggested that IL-17A may be involved in neutrophil recruitment during the wound healing process.
| AdministrationofrIL-17Aleadstodelayed woundhealingandacceleratedaccumulationof neutrophils
To further confirm the role of IL-17A, we examined the effect of rIL-17A administration on the wound healing process. Distinct from IL-17A-KO mice, WT mice treated with rIL-17A showed a significant delay in wound closure on day 3 after wounding compared to those treated with the vehicle control (Fig. 3a, b) . Moreover, collagen deposition was found to be significantly decreased in the rIL-17A-treated group compared with the control group on day 3 (Fig. 3c) .
On the other hand, in mice treated with rIL-17A, the accumulation of leucocytes and neutrophils in the wound tissues was significantly promoted 24 hours after wounding compared with mice treated with the vehicle control, whereas in macrophages and lymphocytes, there was no significant difference between the two groups (Fig. 3d) .
Consistent with these results, the expression of KC was significantly higher in the rIL-17A-treated group than that in the control group 12 hours after wounding (Fig. 3e) .
| Neutrophilelastaseinhibitorimprovesdelayed healing in skin wounds treated with rIL-17A
We hypothesized that neutrophil elastase damaged normal tissues as a causative factor in the delayed wound healing by the treatment with rIL-17A. Therefore, we examined the effect of sivelestat sodium the administration of sivelestat sodium significantly improved the delayed wound closure caused by rIL-17A treatment to the same level as untreated control mice. These results indicate that wound healing was inhibited by neutrophil elastase secreted from neutrophils, which were infiltrated in an IL-17A-dependent manner.
| CellularsourceofIL-17Aproductionand kineticsintheexpressionofIL-17A-relatedmolecules inwoundtissues
Finally, we analysed the cellular source of IL-17A production in wound tissues using WT mice. As shown in Fig. S2a , neutrophils and macrophages as well as γδT cells showed IL-17A expression 24 hours after wounding, whereas NK cells, NKT cells and conventional T cells did not.
It has been reported that IL-1β and IL-23p19 promote the production of IL-17A by innate immune cells like γδT cells 23, 24 and that
RORγt expression is associated with IL-17A production. 25 Therefore,
we estimated the expression of these IL-17A-related molecules using WT mice. As shown in Fig. S2b , the expression of IL-1β and IL-23p19
was significantly increased at 6 and 12 hours and at 6 hours after wounding, respectively. The expression of RORγt tended to increase, although not significantly.
| DISCUSSION
In the present study, IL-17A-KO mice underwent promoted skin wound healing and acceleration in the wound healing-associated processes, including myofibroblasts, collagen-type transition from COL3A1 to COL1A1 and hydroxyproline content, compared with WT mice. In addition, IL-17A deficiency attenuated the accumulation of neutrophils and the expression of KC. In contrast, the administration of rIL-17A induced delayed wound repair, low collagen deposition and the accelerated accumulation of neutrophils and KC expression.
On the other hand, the administration of neutrophil elastase inhibitor improved the delayed wound healing in mice treated with rIL-17A.
Finally, in the wound tissues, neutrophils, macrophages and γδ T cells produced IL-17A, and the expression of IL-17A-related molecules, such as IL-1β and IL-23p19, was found to be increased during wound healing.
In previous studies investigating the role of IL-17A in skin wound (Fig. S3b) . Collectively, these observations may raise a possibility that under the open wound condition, overgrown microbes oppose the healing process that is accelerated in IL-17A-KO mice. However, the precise mechanism underlying the opposite results in these studies remains to be clarified.
In the earlier study, Rodero and co-workers speculated that the promoted wound healing may be associated with the accelerated differentiation of alternative macrophages in the proliferative phase in IL-17A-KO mice. 18 In the current study, we focused on the neutrophils infiltrating the wound tissues and obtained results suggesting that attenuated neutrophil infiltration may be involved in the promoted wound healing under a condition lacking IL-17A production. Neutrophils are the first inflammatory cells to accumulate in skin wounds and remove cellular debris, foreign particles and bacteria. 27 Therefore, they are considered to play an important role in the wound healing process. 10 However, it has recently been reported that in wounds with a low risk of infection, neutrophils delayed wound healing and accelerated scar formation. 28, 29 In the present study, the administration of rIL-17A promoted the neutrophil accumulation and impeded the wound healing.
The delayed wound healing caused by rIL-17A could be explained by a possible mechanism that some neutrophil-derived mediators cause more profound damages to the wound tissues, because neutrophilderived toxic antimicrobial substances and proteases are not only for microbial pathogens but also for self-tissues. 30 Previously, Ashcroft and co-workers reported that mice lacking secretory leucocyte protease inhibitor (SLPI), a protein inhibiting serine proteases such as neutrophil elastase, showed high elastase activity and delayed wound repair compared with WT mice. 31 Furthermore, it has been reported that SLPInull mice showed improved wound repair by replacement with SLPI.
32
In our present study, a neutrophil elastase inhibitor did not show any effect on normal wound healing (data not shown), but restored the delayed wound healing caused by the administration of rIL-17A. These results suggest that the delayed wound healing associated with an increased neutrophil accumulation could be explained in part by tissue damages caused by neutrophil elastase. Other protease inhibitors have been reported to promote chronic wound healing. 33, 34 These inhibitors may also improve acute wound healing impaired through the excess infiltration of neutrophils.
In the wound healing process, TGF-β1 promotes myofibroblast differentiation and collagen deposition in the proliferation phase.
35
These wound healing-associated events can be considered markers that indicate smooth wound healing. 27 In the present study, IL-17A deficiency led to accelerated myofibroblast differentiation, collagen deposition and TGF-β1 production. It has been reported that a lack of IL-17A synthesis promoted the differentiation of alternative macrophages. 18 Indeed, in the current study, macrophages tended to increase after wounding to day 4 in IL-17A-KO mice. Thus, the increased production of these wound healing-associated molecules in IL-17A-KO mice might involve alternative macrophages or a smooth transition from the inflammatory phase to the proliferation phase due to the fade-out of neutrophil infiltration. In the present study, IL-17A deficiency also led to the promoted accumulation of macrophages in the early phase, which might be classical macrophages. It has been reported that the depletion of macrophages in the early stage impairs wound healing, 36 suggesting that an increase in the early-phase accumulation of macrophages may be associated with the accelerated wound healing in IL-17A-KO mice. Further research is necessary to address this point.
The cellular source of IL-17A production in wound tissues has been reported to be γδ T cells in the dermis, 16 dendritic epidermal T cells 17 and macrophages. 18 In the present study, we detected the expression of IL-17A by these cells and also by neutrophils. Recently, neutrophils as well as γδ T cells have been reported to produce IL-17A in psoriasis. 37, 38 In the present study, in the wound healing process,
we found that IL-17A was produced by macrophages and neutrophils as well as γδ T cells. IL-1β and IL-23 promote the production of IL-17A by stimulating γδ T cells, 16, 23 and IL-23 also stimulates IL-17A production by neutrophils. 24 These IL-17A-producing cells express a transcription factor, RORγt, 25,38 whereas γδ T cells expressing T-bet, a Th1-related transcription factor, produce IFN-γ. 39 In the present study, we demonstrated the increased expression of these IL-17A-related molecules after wounding, which suggested that these molecules may be involved in the regulation of the wound healing process by inducing the production of IL-17A.
In conclusion, the present study demonstrated that IL-17A crucially regulated the wound healing process and that accelerated neutrophil accumulation caused by IL-17A led to the delayed wound repair.
Anti-IL-17A mAb therapy has already been used as a treatment for psoriasis, 40 and controlling the bioactivity of IL-17A may lead to a novel approach for the treatment of intractable wounds as well as autoimmune diseases.
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